



(12) Translation of
European patent specification

(11) NO/EP 2826784 B1

NORWAY

(19) NO
(51) Int Cl.
C07H 19/20 (2006.01)
A61K 31/7072 (2006.01)
A61P 31/00 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2019.09.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.06.26
(86)	European Application Nr.	14179358.8
(86)	European Filing Date	2008.03.26
(87)	The European Application's Publication Date	2015.01.21
(30)	Priority	2007.03.30, US, 909315 P 2007.10.24, US, 982309 P 2008.03.21, US, 53015
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(73)	Proprietor	Gilead Pharmasset LLC, c/o Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	Du, Jinfa, 1206 Reins Circle, New HopePA 18938, USA Wang, Peiyuan, 20 Radburn Road, Glen RockNJ 07452, USA Nagarathnam, Dhanapalan, 52 Virginia Rail Drive, BethanyCT 06524, USA Sofia, Michael Joseph, 3066 Antler Road, DoylestownPA 18902, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54)	Title	Composition comprising a HCV NS3 protease inhibitor and a phosphoramidate prodrug of 2'-deoxy-2'-fluoro-2'-C-methyluridine nucleoside
(56)	References Cited:	WO-A2-2008/085508 WO-A2-2005/003147 US-A1- 2006 241 064 CLARK J L ET AL: "Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 6, 15 March 2006 (2006-03-15) , pages 1712-1715, XP027966449, ISSN: 0960-894X [retrieved on 2006-03-15] CLARK J L ET AL: "Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 48, 1 January 2005 (2005-01-01), pages 5504-5508, XP002415215, ISSN: 0022-2623, DOI: 10.1021/JM0502788

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


Patentkrav

1. Farmasøytisk sammensetning omfattende en HCV-NS3-proteaseinhibitor og en forbindelse med følgende formel:



5 2. Farmasøytisk sammensetning ifølge krav 1 til anvendelse i behandling eller profylakse av en infeksjon av hepatitt C-virus eller en sykdom eller tilstand assosiert med eller mediert av hepatitt C-infeksjon, eller de kliniske symptomer derav.

10 3. Forbindelse med følgende formel:



15 til bruk i kombinasjon med en HCV-NS3-proteaseinhibitor i behandling eller profylakse av en infeksjon av hepatitt C-virus eller en sykdom eller tilstand assosiert med eller mediert av hepatitt C-infeksjon, eller de kliniske symptomer derav.

4. Forbindelse til anvendelse ifølge krav 3, hvor forbindelsen blir administrert samtidig med HCV-NS3-proteaseinhibitoren.